Orum Therapeutics Inc (XKRX:475830) Share Price

Company Profile

Business description
Orum Therapeutics Inc is a new drug development biotechnology company that develops anticancer drugs with the technology to attach novel drug payloads to ADC. It can develop all three components of ADC, which consist of antibodies, payloads, and linkers, in-house. The group pioneering a class of therapeutics intended to expand the universe of druggable targets and to meaningfully improve upon potency and tolerability, thereby improving the therapeutic window of drugs. Its services include the modeling, research, development, and testing of pharmaceuticals and treatments for such diseases for Orum’s partners and licensees. The pipeline products are TPD2GSPT1, TPD2PROTAb, and TPS2Cbl-b.
Contact
Munji-ro
281-25, 2nd floor
Yuseong-gu
Daejeon
KOR
T: +82 427163030
https://www.orumrx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
17

Recommended

Going back to my original thesis to evaluate a position.

Mark LaMonica, CFA | 08 August 2025

This company dominates its industry and could be flirting with regulatory intervention.

Roy Van Keulen | 07 August 2025

Uber’s business is humming along but autonomous vehicles add uncertainty to the longer term outlook.

Mark Giarelli | 07 August 2025

Index	Last price	Change	% Change
All Ordinaries	9,076.60	25.40	-0.28%
CAC 40	7,743.00	33.68	0.44%
DAX 40	24,162.86	29.64	-0.12%
Dow JONES (US)	44,175.61	206.97	0.47%
FTSE 100	9,095.73	5.04	-0.06%
HKSE	24,858.82	222.81	-0.89%
NASDAQ	21,450.02	207.32	0.98%
Nikkei 225	41,820.48	761.33	1.85%
NZX 50 Index	12,844.63	42.47	-0.33%
S&P 500	6,389.45	49.45	0.78%
S&P/ASX 200	8,807.10	24.30	-0.28%
SSE Composite Index	3,635.13	4.54	-0.12%